Response to platinum-based therapies in second-line after immunotherapy in advanced or metastatic non-small-cell lung cancer PD-L1 ≥50%
The current response to second-line platinum-based therapies for patients with advanced NSCLC after immunotherapy appears to achieve favourable response rates and be an optimal treatment after progression to immunotherapy. Prior immunotherapy appears to enhance these patients' platinum response, though future confirmatory studies are necessary.
Authors
- Emilio Fonseca‐Sánchez (ORCID: https://orcid.org/0000-0001-7363-6454)
- E. del Barco (ORCID: https://orcid.org/0000-0001-6443-0585)
- Luis Posado-Domínguez (ORCID: https://orcid.org/0009-0005-4606-2316)
- Lorena Hernandez (ORCID: https://orcid.org/0000-0001-5339-7222)
- Alejandro Olivares-Hernández (ORCID: https://orcid.org/0000-0003-1992-6105)
- Laura Corvo-Félix
- Juan Carlos Redondo-González (ORCID: https://orcid.org/0009-0001-7368-2263)
Institutions
- Universidad de Salamanca (ES)
- Instituto de Investigación Biomédica de Salamanca (ES)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2024-10-01
- DOI
- https://doi.org/10.21037/tlcr-24-513
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00